

RECEIVED

OCT 22 2002

TECH CENTER 1600/2900

EXPRESS MAIL CERTIFICATE

10/17/02 2208552597-05

Date Label No.

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Commissioner of Patents and Trademarks, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

D B Peck

Signature

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR
CREDIT ANY EXCESS IN THE FEES DUE WITH THIS
DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

10/18
Adam
11/1/02

Name (Print)

Signature

Customer No.:



07278

PATENT TRADEMARK OFFICE

Docket No.: 5432/01004US0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ken LILJEGREN et al.

Serial No.: 09/730,380

Confirmation No.: 7399

Art Unit: 1625

Filed: December 5, 2000

Examiner: C. AULAKH

For: PHARMACEUTICAL COMPOSITION CONTAINING CITALOPRAM

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a copy of Form PTO-1449 and copies of the documents listed thereon.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the

attached Form PTO-1449) be given thorough consideration and that it be cited of record in the

10/21/2002 NMCHAM1 00000111 09730300

prosecution history of the present application by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Reference 1 is a U.S. equivalent of reference 3.


Accompanying this Information Disclosure Statement is the statutory fee of \$180.00 under 37 C.F.R. 1.17(p). The Commissioner is authorized to charge any additional fees required in connection with this Petition or to credit any overpayment to Deposit Account No. 04-0100.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

Dated: October 17, 2002


John C. Todaro
Registration No. 36,036
Attorney for Applicant(s)

DARBY & DARBY
Post Office Box 5257
New York, NY 10150-5257
(212) 527-7700

M:\5432\0I004\LWJ8915.WPD

Serial No. 09/730,380

Docket No. 5432/0I004US0